San Francisco, CA, United States of America

Thomas Son

USPTO Granted Patents = 2 

Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2021-2023

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovations by Thomas Son in Antibody Drug Conjugates

Introduction

Thomas Son is an accomplished inventor based in San Francisco, CA. He has made significant contributions to the field of biotechnology, particularly in the development of antibody drug conjugates. With a total of 2 patents, his work focuses on innovative solutions for cancer treatment.

Latest Patents

Thomas Son's latest patents revolve around B7-H3 directed antibody drug conjugates. These inventions are aimed at creating novel B7-H3-binding molecules that can effectively bind to both human and non-human B7-H3. The patents detail the development of bispecific, trispecific, or multispecific B7-H3-binding molecules, which include various forms such as bispecific diabodies and BiTEs. Additionally, the inventions encompass pharmaceutical compositions that utilize these B7-H3-binding molecules for treating cancer and other diseases.

Career Highlights

Thomas Son is currently associated with Macrogenics, Inc., where he continues to push the boundaries of medical science through his innovative research. His work has the potential to significantly impact cancer therapies and improve patient outcomes.

Collaborations

Some of his notable coworkers include Deryk T Loo and Ling Ling Huang, who contribute to the collaborative environment that fosters innovation at Macrogenics, Inc.

Conclusion

Thomas Son's contributions to the field of biotechnology, particularly through his patents on B7-H3 directed antibody drug conjugates, highlight his role as a leading inventor in cancer treatment innovations. His work exemplifies the intersection of science and technology in addressing critical health challenges.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…